insulin sensitivity
Conditions
Interventions
Intervention: Patients will be treated with sodiumbutyrate orally once daily during 4 weeks
Sponsors
AMC-UvA
Eligibility
Inclusion criteria
Inclusion criteria: Healthy lean male volunteers (N=10, BMI 19-25 kg/m2) and obese insulin resistant male volunteers (N=10) matched for age will be recruited and tested for BAT activity and insulin sensitivity before and after oral butyrate treatment.
Exclusion criteria
Exclusion criteria: - Any Medication or probiotic use - Smoking - Participation in a research protocol involving radiation exposure in the last 2 years. - eGFR <60 ml/min
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary objective: To investigate whether butyrate influences the metabolic activity of BAT (as assessed with a FDG-PET CT scan) in relation to hepatic and peripheral insulin sensitivity (two step hyperinsulinemic normoglycemic clamp). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary Objectives: -To determine whether differences in resting energy expenditure during thermoneutral conditions correlate with the metabolic BAT activity before and after butyrate treatment. - To determine if fecal gutmicrobiota and fecal energy excretion are altered upon oral butyrate treatment. -Changes in expression of genes involved in insulin phosphorylation signalling pathways, inflammation and lipid synthesis in subcutaneous fat upon oral butyrate supplementation. - changes in plasma (monocyte) and subcutaneous adipose tissue inflammatory markers upon 4 weeks of butyrate treatment. | — |
Contacts
Public ContactM. Nieuwdorp
AFDELING INWENDIGE GENEESKUNDE AMC MEIBERGDREEF 9, KAMER F4.159.2
Outcome results
None listed